Literature DB >> 26763999

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Shilpa Patil1, Rajesh Kumar1, Suprit Deshpande1, Sweety Samal1, Tripti Shrivastava1, Saikat Boliar1, Manish Bansal1, Nakul Kumar Chaudhary1, Aylur K Srikrishnan2, Kailapuri G Murugavel2, Suniti Solomon2, Melissa Simek3, Wayne C Koff3, Rajat Goyal3, Bimal K Chakrabarti4, Jayanta Bhattacharya5.   

Abstract

UNLABELLED: Broadly neutralizing antibodies isolated from infected patients who are elite neutralizers have identified targets on HIV-1 envelope (Env) glycoprotein that are vulnerable to antibody neutralization; however, it is not known whether infection established by the majority of the circulating clade C strains in Indian patients elicit neutralizing antibody responses against any of the known targets. In the present study, we examined the specificity of a broad and potent cross-neutralizing plasma obtained from an Indian elite neutralizer infected with HIV-1 clade C. This plasma neutralized 53/57 (93%) HIV pseudoviruses prepared with Env from distinct HIV clades of different geographical origins. Mapping studies using gp120 core protein, single-residue knockout mutants, and chimeric viruses revealed that G37080 broadly cross-neutralizing (BCN) plasma lacks specificities to the CD4 binding site, gp41 membrane-proximal external region, N160 and N332 glycans, and R166 and K169 in the V1-V3 region and are known predominant targets for BCN antibodies. Depletion of G37080 plasma with soluble trimeric BG505-SOSIP.664 Env (but with neither monomeric gp120 nor clade C membrane-proximal external region peptides) resulted in significant reduction of virus neutralization, suggesting that G37080 BCN antibodies mainly target epitopes on cleaved trimeric Env. Further examination of autologous circulating Envs revealed the association of mutation of residues in the V1 loop that contributed to neutralization resistance. In summary, we report the identification of plasma antibodies from a clade C-infected elite neutralizer that mediate neutralization breadth via epitopes on trimeric gp120 not yet reported and confer autologous neutralization escape via mutation of residues in the V1 loop. IMPORTANCE: A preventive vaccine to protect against HIV-1 is urgently needed. HIV-1 envelope glycoproteins are targets of neutralizing antibodies and represent a key component for immunogen design. The mapping of epitopes on viral envelopes vulnerable to immune evasion will aid in defining targets of vaccine immunogens. We identified novel conformational epitopes on the viral envelope targeted by broadly cross-neutralizing antibodies elicited in natural infection in an elite neutralizer infected with HIV-1 clade C. Our data extend our knowledge on neutralizing epitopes associated with virus escape and potentially contribute to immunogen design and antibody-based prophylactic therapy.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26763999      PMCID: PMC4794693          DOI: 10.1128/JVI.03090-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.

Authors:  Patrick R Harrington; Julie A E Nelson; Kathryn M Kitrinos; Ronald Swanstrom
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

2.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.

Authors:  Cecilia Rademeyer; Penny L Moore; Natasha Taylor; Darren P Martin; Isaac A Choge; Elin S Gray; Haynes W Sheppard; Clive Gray; Lynn Morris; Carolyn Williamson
Journal:  Virology       Date:  2007-07-16       Impact factor: 3.616

4.  Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Authors:  E S Gray; P L Moore; I A Choge; J M Decker; F Bibollet-Ruche; H Li; N Leseka; F Treurnicht; K Mlisana; G M Shaw; S S Abdool Karim; C Williamson; L Morris
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

Review 5.  Immunoglobulin somatic hypermutation.

Authors:  Grace Teng; F Nina Papavasiliou
Journal:  Annu Rev Genet       Date:  2007       Impact factor: 16.830

6.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Authors:  Elin S Gray; Penny L Moore; Frederic Bibollet-Ruche; Hui Li; Julie M Decker; Tammy Meyers; George M Shaw; Lynn Morris
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Authors:  Yuxing Li; Krisha Svehla; Mark K Louder; Diane Wycuff; Sanjay Phogat; Min Tang; Stephen A Migueles; Xueling Wu; Adhuna Phogat; George M Shaw; Mark Connors; James Hoxie; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

View more
  14 in total

1.  Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Authors:  Narayanaiah Cheedarla; Jagadish Chandrabose Sundaramurthi; Babu Hemalatha; Brahmaiah Anangi; Manohar Nesakumar; Manickam Ashokkumar; K K Vidya Vijayan; Srikanth Prasad Tripathy; Soumya Swaminathan; S Kalyanaraman Vaniambadi; D Vadakkupattu Ramanathan; Luke Elizabeth Hanna
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-20       Impact factor: 2.205

2.  The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec.

Authors:  Rajaiah Pergu; Sunayana Dagar; Harsh Kumar; Rajesh Kumar; Jayanta Bhattacharya; Sivaram V S Mylavarapu
Journal:  J Biol Chem       Date:  2019-03-15       Impact factor: 5.157

3.  A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.

Authors:  Nitin Hingankar; Suprit Deshpande; Payel Das; Zaigham Abbas Rizvi; Constantinos Kurt Wibmer; Poppy Mashilo; Mohammed Yousuf Ansari; Alison Burns; Shawn Barman; Fangzhu Zhao; Sohini Mukherjee; Jonathan L Torres; Souvick Chattopadhyay; Farha Mehdi; Jyoti Sutar; Deepak Kumar Rathore; Kamal Pargai; Janmejay Singh; Sudipta Sonar; Kamini Jakhar; Jyotsna Dandotiya; Sankar Bhattacharyya; Shailendra Mani; Sweety Samal; Savita Singh; Pallavi Kshetrapal; Ramachandran Thiruvengadam; Gaurav Batra; Guruprasad Medigeshi; Andrew B Ward; Shinjini Bhatnagar; Amit Awasthi; Devin Sok; Jayanta Bhattacharya
Journal:  PLoS Pathog       Date:  2022-04-28       Impact factor: 7.464

4.  Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.

Authors:  Ranajoy Mullick; Jyoti Sutar; Nitin Hingankar; Suprit Deshpande; Madhuri Thakar; Seema Sahay; Rajesh P Ringe; Sampurna Mukhopadhyay; Ajit Patil; Shubhangi Bichare; Kailapuri G Murugavel; Aylur K Srikrishnan; Rajat Goyal; Devin Sok; Jayanta Bhattacharya
Journal:  Retrovirology       Date:  2021-05-14       Impact factor: 4.602

5.  Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.

Authors:  Suprit Deshpande; Shilpa Patil; Rajesh Kumar; Tripti Shrivastava; Aylur K Srikrishnan; Kailapuri G Murugavel; Wayne C Koff; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  Retrovirology       Date:  2016-06-15       Impact factor: 4.602

6.  The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

Authors:  Sara L Bissett; Anna Godi; Simon Beddows
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

7.  Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.

Authors:  Rajesh Kumar; Gabriel Ozorowski; Vivek Kumar; Lauren G Holden; Tripti Shrivastava; Shilpa Patil; Suprit Deshpande; Andrew B Ward; Jayanta Bhattacharya
Journal:  J Biol Chem       Date:  2017-07-25       Impact factor: 5.157

8.  Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.

Authors:  Narayanaiah Cheedarla; Babu Hemalatha; Brahmaiah Anangi; Kannan Muthuramalingam; Murugesan Selvachithiram; Pattabiraman Sathyamurthi; Nandagopal Kailasam; Raghavan Varadarajan; Soumya Swaminathan; Srikanth Prasad Tripathy; S Kalyanaraman Vaniambadi; D Ramanathan Vadakkupattu; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2018-03-27       Impact factor: 7.561

9.  HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.

Authors:  Suprit Deshpande; Shilpa Patil; Rajesh Kumar; Tandile Hermanus; Kailapuri G Murugavel; Aylur K Srikrishnan; Suniti Solomon; Lynn Morris; Jayanta Bhattacharya
Journal:  Retrovirology       Date:  2016-08-30       Impact factor: 4.602

10.  Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

Authors:  Narayanaiah Cheedarla; K Lucia Precilla; Hemalatha Babu; K K Vidya Vijayan; Manickam Ashokkumar; Padmapriyadarsini Chandrasekaran; Nandagopal Kailasam; Jagadish Chandrabose Sundaramurthi; Soumya Swaminathan; Viswanath Buddolla; S Kalyanaraman Vaniambadi; V D Ramanathan; Luke Elizabeth Hanna
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.